Extended adjuvant (adj) neratinib in HER2+/HR+ early breast cancer (eBC) in clinical routine – interim analysis of the multinational, prospective, non-interventional study (NIS) ELEANOR

15. Januar 2026

U. Breitenstein, D. Wrobel, D. Guth, M. Zaiss, J. Terhaag, M.-O. Zahn, L. Perlova-Griff, A. Distelrath, R. Würstlein, K. Apel, N. Deuerling, C. Vannier, R. Bartsch, C. Jackisch, V. Müller, M. Schmidt, M. Balic, G. Rinnerthaler, D. Lüftner, K. Zaman, M. Schwitter, N Harbeck.

The Breast, Volume 80, Supplement, 2025, 103911, https://doi.org/10.1016/j.breast.2025.103911

Poster